plated that said mammalian cells may be selected from the group consisting of normal cells and cancerous cells. It is further contemplated that the method of decreasing the expression of p33ING1 will comprise introducing into said mammalian cells at least one composition selected from the group consisting of p33ING1 and nucleotides which code for p33ING1.
Another aspect of the invention provides a method of diagnosing breast cancer comprising obtaining a biological sample comprising mammary cells suspected of being neoplastic and determining whether or not the biological sample contains p33ING1 or the DNA which encodes p33ING1, wherein the presence of p33ING1 or its DNA denotes non-cancerous cells.
Another aspect of the invention provides a method of diagnosing breast cancer comprising obtaining a biological sample comprising mammary cells suspected of being neoplastic, contacting said biological sample with at least one antibody to p33ING1 under conditions wherein antibody binding to p33ING1 occurs; and detecting whether or not said antibody binds to said cells, wherein binding to said cells indicates that said cells are non-cancerous.
One aspect of the invention provides nucleic acid isolates greater than 10 nucleotides in length which are substantially identical to the DNA sequence of FIG. 3 or its complement. Recombinant expression vectors comprising such sequences and cells transformed with such recombinant expression vectors are also provided.
One other aspect of the invention provides for a nucleic acid sequence which encodes the amino acid sequence of FIGS. 2 or 3 and recombinant expression vectors comprising such sequences and cells transformed with such recombinant expression vectors.
One other aspect of the invention provides for peptides and proteins having p33ING1 biological activity. It is contemplated that such peptides will have an amino acid sequence substantially identical to the amino acid sequence set forth in FIGS. 2 or 3.
Still a further aspect of the invention provides for antibodies to the p33ING1 protein.
A further aspect of the invention provides methods for decreasing proliferation of cancer cells in a patient comprising administering an effective amount of the above-described nucleic acid isolates, nucleic acid sequences, proteins or peptides under conditions wherein p33ING1 is expressed in the cancer cells. It is contemplated that the cancer is selected from the group consisting of breast and brain cancers.
Another further aspect of the invention provides methods of increasing cell proliferation of mammalian cells by decreasing expression of p33ING1 in the cells. It is contemplated that such methods could include the administration of either a single-stranded oligonucleotide comprising a sequence substantially identical to the complement of the cDNA sequence of FIG. 3 or the administration of a single or
plated that said mammalian cells may be selected from the group consist of normal cell and cancerous cells. It is further contemplated that the method acting of decreasing the expression of p33ING1 will comprise introduce into said mammalian cells at least one constitution selected from the group consisting of p33ING1 and nucleotide which code for p33ING1. 
 Another aspect of the invention provides a method of diagnosing breast cancer constitute obtaining a biological sample comprising mammary cells suspected of being neoplastic and determine whether or not the biological sample contains p33ING1 or the DNA which encode p33ING1, wherein the presence of p33ING1 or its DNA denotes non - cancerous cells. 
 Another view of the invention provides a method acting of diagnosing breast cancer incorporate obtaining a biological sample comprising mammary cell suspected of being neoplastic, contacting said biological sample with at least one antibody to p33ING1 under conditions wherein antibody bind to p33ING1 occurs; and detecting whether or not said antibody binds to said cells, wherein binding to said cells indicates that say cells are non - cancerous. 
 One aspect of the invention provide nucleic acid isolates greater than 10 nucleotides in length which are well identical to the DNA sequence of FIG. 3 or its complement. Recombinant formula vectors comprising such sequence and cells transformed with such recombinant expression vectors are besides provided. 
 One other aspect of the invention provides for a nucleic acid sequence which encodes the amino acid sequence of FIGS. 2 or 3 and recombinant saying vectors comprising such sequences and cells transformed with such recombinant formula vectors. 
 One other aspect of the invention provide for peptides and proteins having p33ING1 biological activity. It is chew over that such peptides will take an amino acid sequence well identical to the amino acid sequence set forth in FIGS. 2 or 3. 
 Still a further view of the invention provides for antibody to the p33ING1 protein. 
 A further aspect of the invention provides methods for decrease proliferation of cancer cells in a patient comprising administer an effective amount of the above - report nucleic acid isolates, nucleic acid sequences, proteins or peptides under conditions wherein p33ING1 is expressed in the cancer cell. It is contemplated that the cancer is selected from the group consist of breast and brain cancers. 
 Another further expression of the invention provides methods of increasing cellular telephone proliferation of mammalian cells by decreasing expression of p33ING1 in the cells. It is contemplated that such methods could include the administration of either a single - ground oligonucleotide consist a sequence substantially identical to the complement of the cDNA sequence of FIG. 3 or the administration of a single or
plahed that said mammalian gells may be selgcred frmm the group cunsisting of normal cells anv cabceroys cells. It is further contemplwted thar tht method of decreeaing thc expdcssiou if p33ING1 will cpmprise indroducing into sxib mammalian cells at least one compofition xepected from thg grolp conapsuing of p33ING1 and nucleotides whicg code hor p33ING1.
Another aspect of the invention pgovifes a method of diwgnosing brgzst xancer comprksing obtapuing a biolkgical sample comprising mammarh celks suspectgb of teing neoplestic wnd determinlmg whedher or not the biolonical sanple contains p33ING1 or the DNA which encjdes p33ING1, wkerein the presence od p33ING1 mr ids DVQ ddnoues nkn-cancfrons cells.
Anofher aspect of the invention ptodpces a method of diwggosing breast cancer comprising obtainitg z biological sample comprising mammary cells suspecteq of being neoplastic, contacting said biological vamplx ditk at ldqsh one antibody to p33ING1 under conditions whereyh snnibody binding to p33ING1 occurx; wnc detecting whgther ox nkt said antibody blnds to said cells, whtrein binding to said cells indixates that scid cells are non-canczrous.
One aspzct of the onvention provides nuclzic acjd isolates greater ffan 10 nucleotides in langth which are substantiajly identmcal co the DVA sgquence of FIG. 3 og its complement. Recombijant gxpresvion vectogs comprising such sequences anv cells transgosmeg with sbch regombinant exprefsion vectors cre also provkded.
One otger aspxct of the igvention provhfes for a nurleic aciq sewuenxe whicf encodes the akino acid sequence if FIGS. 2 or 3 and rccombkhant expression vextors comprisinb sjch svquxnces dnd cells trdnsfurmdc witf such reconcinamt expression vectorv.
One other aspect of tne inventiin proviqes for peptices and proteins hwving p33IIG1 biokogycal activity. It is contemplatsd that skch peptides wijl hqve an amino acid sequence substantially identical vo the amino acid sequgnce set forth in FIGX. 2 or 3.
Still e furtrer aspecd of the invention peovides for antibpdies to the p33ING1 profein.
A xurthfr aspect of the invention provides methods for decreasing proliferation if canrew cells in z payient cjkprisigg avmmnistering an effvctive amount of the above-descriued nucleiw ccid isolates, nucleic acid seaudnces, proteinr or peptides under condjtions wnerein p33ING1 is expressed in the cancer cells. It is contcmplated rhat fhe cancer is selected from yhe grmup cinsistibg on breast and bfaim gancers.
Anohher fbrther aspect of the invention privides mfthods of increaving cell pvouiferztion jf mammalian celms bg decrgasing expressoon of p33ING1 in the cells. It is connem[lated that suxg methods coold incllde the adminmstration of either a single-stranded oligonucleotide comprising a sequende substaitially identivel to the complement of bhe cQNA sequdnce of FIG. 3 or the administration of a single or
plated that said mammalian cells may be the consisting of cells and cancerous that method of decreasing expression of p33ING1 comprise introducing into said mammalian cells least one composition selected from the group consisting of p33ING1 and nucleotides which for p33ING1. Another aspect of the invention provides a method of diagnosing breast comprising a sample mammary cells suspected of being neoplastic and determining whether or not the biological sample contains p33ING1 the DNA which encodes p33ING1, wherein the presence p33ING1 or its DNA non-cancerous cells. Another aspect of invention a method diagnosing cancer obtaining a biological comprising mammary cells suspected of being neoplastic, contacting said biological sample with at least one antibody to under conditions binding to occurs; detecting or not said to said cells, wherein binding to that said cells are non-cancerous. One aspect of invention provides acid isolates greater than 10 nucleotides length which are substantially identical to the DNA of FIG. 3 or its complement. Recombinant expression vectors comprising such sequences and cells transformed recombinant expression vectors are provided. One other of invention for nucleic acid which encodes the amino acid sequence of FIGS. 2 or 3 recombinant expression vectors comprising such sequences and cells transformed with expression One other aspect the invention provides for and having p33ING1 biological activity. contemplated such an acid substantially identical to the acid sequence set forth in 2 or 3. Still invention provides for antibodies to the p33ING1 protein. further aspect of the invention provides methods decreasing proliferation of cancer cells in a patient comprising administering an effective of the acid isolates, nucleic acid sequences, proteins or peptides conditions wherein p33ING1 is in the cancer cells. It is contemplated that the is from the consisting of breast brain cancers. Another aspect of the methods of cell of decreasing expression of p33ING1 in the It contemplated that such methods could the either a single-stranded oligonucleotide comprising a sequence substantially identical to the complement of the cDNA FIG. 3 or the of single or
plated that said mammalian ceLls may be seLecteD frOm tHe GrouP conSisting of normaL CellS and cancerous cells. It is FurthEr COnteMPlAted tHat the mEThOD Of dEcReAsiNg THe ExpreSsiOn of p33INg1 will comprIse InTroducing intO SaId mammaliaN ceLls at least onE coMpositIoN seLEcted FroM the gRoup coNSistinG of p33ING1 anD nUCleotiDEs which CODe For p33iNG1.
Another aspect oF ThE Invention proviDes a meThOD oF DIagNosIng breast cAnCer coMPrising OBtAINIng A Biological samPle comprisiNG maMmary cElLs sUSpecteD of beInG NeoPlastic and dEterMining wheTher or NOt the biOLogical Sample ConTaiNs p33Ing1 oR tHe DnA WHicH EnCodES p33InG1, whereiN tHe PreseNce oF P33ing1 or iTs DnA deNotes Non-cancerous cEllS.
AnoTHer AspecT of thE invEnTion pRovideS a metHoD of diagnosing brEast Cancer comPriSiNg oBtAininG A bioloGicAl sAmple coMprisinG MamMaRY CElLs suspected of being NeOPLaStic, contActing SAiD bIOlogical SaMplE witH AT leasT one ANtIbody to p33iNG1 undER cOnDitions WhErein aNtIboDy bIndinG To p33InG1 occuRs; and detEctinG Whether or not saID antibody bindS To SAId CElls, WheRein binding To saID celLs inDIcAteS That sAid ceLlS ArE Non-cancerous.
One aspeCt Of the iNventIon provides nuCleic acid iSOLAtes greaTer tHAn 10 NUcleotides in leNgth wHich are subSTantiallY idenTical to tHe DNA sequENCe of FIG. 3 oR itS coMplEmeNT. reCombinant exprESSion VeCtors coMprIsing suCh sEquEncEs aNd Cells tranSformed wItH sUcH rEcoMbinaNT expressIoN veCtOrs Are alSO proviDed.
OnE othEr AsPEct Of the inVEnTIOn prOvIdEs foR a nUcLeic aCid sEQueNce whicH encodes tHe aMIno aCiD sEquence Of FIGS. 2 or 3 and reCoMbinant expReSsiOn vectORS comprisIng such sequences and cellS TransfoRmeD with Such RecombinaNt eXpressIon VEctors.
one othEr aspEcT of THE inveNTIoN prOvIdes for pepTIDes And prOtEins Having p33iNG1 biological activITy. IT is contemplatEd tHat sUCH pEptIDeS WilL hAVe aN AMino acid sequencE substantiAlLY iDentical to THe aMiNo acid sEquence Set foRTh in FIGs. 2 or 3.
Still a Further asPeCt of THE inVention proVides for AntibodieS To the P33iNg1 protEin.
a furthEr AspEct of The invENtiOn proVides mEtHods foR decrEaSing prolIferation of cancer cells iN a patiEnt coMprIsing admiNisTEriNg an effecTive Amount of thE abOve-DescrIbeD NucleIc acID iSolATes, nuCleiC Acid sequeNCeS, prOTEiNs or peptideS UNDer CondiTioNS whereIn p33InG1 is expressed in thE Cancer cells. It iS conTEMplAteD That ThE cancer is selecTed FrOM The group CoNsisting of bReast and BrAIn canCers.
AnOther fUrther aSPEcT Of the iNvenTioN provides MetHoDS of incrEaSiNG cell pRoliFeRation Of mammALian CELls by decreasing eXpresSIOn of p33inG1 iN the cElLs. It is cONtemPlated that Such methods Could iNcluDe the AdminisTrAtion oF eiThEr a single-sTRanded oliGonucLeotide CoMpriSinG a sequEnce SUBstanTialLy IdeNtical to tHE CoMPlEmENt oF the CDNA sEqUencE of FIG. 3 or tHE adminisTraTIon of a sInGle OR
plated that said mammalian  cells may  be s ele cte dfrom  the  group consist i ng o f normal cells and can cerou sc ells .  I t isfurther co n t emp la te d t ha t  t he me tho d of de creasing t heex pression ofp 33 ING1 willcom prise introd uci ng int osai d  mamm ali an ce lls at leastone compo si t ion se l ected f r o mthegroup consistingo fp 33ING1 and nuc leotid es wh i c h c ode  for p33IN G1 .
Ano t her asp e ct o f  th e  invention pr ovides a me t hod  of di ag nos i ng bre ast c an c ercomprisingobta ining a b iologi c al samp l e compr isingmam mar y ce l ls  s usp ec t edo fbei n g n eoplasti can d det ermi n i n g  whe the r or  notthe biologica l s ampl e  co ntain s p33 ING1  o r the  DNA w hichen codes p33ING1,wher ein the p res en ceof  p33I N G1 orits  DN A denot es non- c anc er o u s  c ells.
Another aspe ct o fthe inve ntionp ro vi d es a met ho d o f di a g nosin g br e as t cancer  compr i si ng  obtain in g a bi ol ogi cal  samp l e co mprisi ng mamma ry ce l ls suspected o f  being neopla s ti c ,  c o ntac tin g said biol ogic a l sa mple wi tha t lea st on ea nt i body to p33ING1 und er  condi tions  wherein anti body bindi n g to p33IN G1 o c cu r s; and detecti ng wh ether or n o t said a ntibo dy binds  to saidc e lls, whe rei n b ind ing t osaid cells in d i cate sthat sa idcells a renon -ca nce ro us.
One a spect of  t he  i nv ent ion p r ovides n uc lei caci d iso l ates g reate r th an  1 0  nu cleotid e si n  len gt hwhic h a re  subs tant i all y ident ical to t heD NA s eq ue nce ofFIG. 3 or its  c omplement.  R eco mbinan t expressi on vectors comprising s u ch sequ enc es an d ce lls trans for med wi ths uch re combin ant e xp res s i on ve c t or s a re  also prov i d ed. 
Oneot heraspectof the invention p r ovi des for a nuc lei c ac i d  s equ e nc e  wh ic h  en c o des the amino a cid sequen ce of  FIGS. 2 o r  3an d recom binantexpre s sion ve ctors com prising s uc h se q u enc es and cel ls trans formed wi t h suc h  r ecomb ina nt exp re ssi on ve ctors. One  othe r aspe ct  of th e inv en tion pro vides for peptides andprotei ns ha vin g p33ING1  bi o log ical acti vity . It is co nte mpl atedtha t  such  pep t id esw ill h avea n amino a c id  se q u en ce substant i a l lyident ica l  to th e am ino acid sequence set forth in F IGS. 2  or  3. Stil la further aspe ctof t he inven ti on provides  for ant ib o diesto the  p33IN G1 prot e i n. A furt herasp ect of th e i nv e ntion p ro vi d es met hods  f or dec reasin g  pro l i feration of canc er ce l l s ina  pa tient  c omprisi n g ad ministerin g an effect ive am ount  of t he abov e- descri bed  n ucleic aci d  isolates , nuc leic ac id  seq uen ces, p rote i n s orpept id esunder con d i ti o ns  w h ere in p 33ING 1is e xpressedi n the ca nce r  cells.  I t i s contem p la t e d that the  ca nceri s  selectedf romt he group  consi stingof brea s t a nd  braincan c e rs.
Anoth er furthe r  as pe ct o f the in ve ntio npro vi des methods ofincreasi ng cellp r olifer ati o n of mammal ia n cells by d ecrea si n g expre s s ion  of p33 I NG1  in  th e ce lls . It is contemplated that suc h me thods cou ld in clude  t he admin i stra tion ofe ither a singl e-stranded olig o nuc l eoti dec om pr ising a s equ e nce s ubst ant iall y i dent i c al t o  the co mple ment o f th ecD NA sequen ce  of FIG .  3 o r  th e ad minis tr at i on  of a s ingle or 
plated that_said mammalian_cells may be selected_from the_group_consisting of_normal_cells and cancerous_cells. It is_further contemplated that the_method of decreasing_the_expression of p33ING1 will comprise introducing into said mammalian cells at least one composition_selected_from the_group_consisting_of p33ING1 and nucleotides which_code for p33ING1.
Another aspect of_the invention_provides a method of diagnosing breast cancer comprising_obtaining_a biological sample_comprising mammary cells suspected of being neoplastic and determining_whether or not the biological sample_contains p33ING1 or_the_DNA_which encodes p33ING1, wherein_the presence of p33ING1 or its_DNA denotes non-cancerous cells.
Another aspect of_the invention provides a method of diagnosing_breast cancer comprising obtaining a biological_sample comprising mammary cells suspected_of being_neoplastic, contacting said biological sample_with at least_one antibody_to p33ING1 under_conditions wherein antibody binding to p33ING1_occurs; and detecting_whether or not said antibody binds_to_said cells, wherein_binding_to_said cells_indicates that said_cells_are non-cancerous.
One_aspect_of the invention provides nucleic acid_isolates_greater than 10 nucleotides in length which_are substantially identical to_the_DNA sequence of FIG._3 or its complement. Recombinant_expression vectors comprising such sequences and_cells transformed_with such_recombinant expression vectors are also provided.
One other aspect of the invention_provides for a nucleic acid sequence_which encodes the amino_acid sequence_of_FIGS. 2 or_3_and recombinant_expression vectors comprising such sequences and cells_transformed with_such recombinant expression vectors.
One other aspect_of the invention provides_for_peptides and proteins having p33ING1 biological_activity. It is contemplated that such_peptides will have an amino_acid_sequence_substantially identical to the amino_acid sequence set forth in FIGS._2 or 3.
Still_a further aspect of the invention provides_for_antibodies to the p33ING1 protein.
A further_aspect_of the invention provides methods for_decreasing_proliferation_of cancer cells in a_patient comprising administering an effective amount_of the above-described nucleic acid isolates, nucleic acid sequences,_proteins or peptides_under conditions wherein p33ING1 is_expressed_in_the cancer cells. It is contemplated that the cancer is_selected from_the group consisting_of breast and brain cancers.
Another further aspect of the invention_provides methods of increasing cell proliferation of_mammalian cells by decreasing expression of p33ING1 in the cells. It_is contemplated that such methods could include the_administration of either a single-stranded oligonucleotide comprising_a sequence substantially identical_to_the complement of the cDNA sequence of_FIG._3_or_the administration of_a single or